Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Life Sciences
Antiviral Activities Andphosphorylation Of 5-Halo-2'-Deoxyuridines And N-Methanocarbathymidine In Cells Infectedwith Vaccinia Virus, Donald F. Smee, D. E. Humphreys, B. L. Hurst, Dale L. Barnard
Antiviral Activities Andphosphorylation Of 5-Halo-2'-Deoxyuridines And N-Methanocarbathymidine In Cells Infectedwith Vaccinia Virus, Donald F. Smee, D. E. Humphreys, B. L. Hurst, Dale L. Barnard
Animal, Dairy, and Veterinary Science Faculty Publications
The Antipoxviral activities and phosphorylation of N-methanocarbathymidine ([N]-MCT) and four 5-halo-2'-deoxyuridines, namely 5-flouro- (FdU), 5-chloro- (CldU), 5-bromo- (BrdU), and 5-iodo- (IdU) derivatives were explored.
Interferon-Alpha, Dale L. Barnard
Interferon-Alpha, Dale L. Barnard
Animal, Dairy, and Veterinary Science Faculty Publications
Amarillo Biosciences is developing low-dose oral interferon-alpha (IFNalpha; Veldona) as a potential treatment for primary Sjøgren's syndrome, oral mucositis in cancer patients, hepatitis B and C virus (HBV and HCV) infections, and bone marrow disorders. The company is also developing a topical formulation of IFNalpha for the potential treatment of genital warts. The product is registered in Ghana for the treatment of HBV infection. In October 2001, Amarillo licensed rights to its low-dose oral IFNalpha to Atrix Laboratories for the Orphan indications of oral papillomavirus and Behçet's disease.
Genvir, Dale L. Barnard
Genvir, Dale L. Barnard
Animal, Dairy, and Veterinary Science Faculty Publications
Flamel Technologies is developing Genvir (formerly known as Viropump), a twice-daily controlled-release formulation of aciclovir, for potential use in the treatment of herpes simplex virus and varicella zoster virus infections. Genvir utilizes Flamel's proprietary Micropump technology, a microparticle-based drug delivery system designed to extend the time of absorption of drugs in the small intestine. The drug shows a comparable therapeutic efficacy to valaciclovir and famciclovir (both GlaxoSmithKline) [313393]. Phase III trials have been completed [302829]. In August 2000, Flamel filed for regulatory approval for the treatment of herpes in France, as a prelude to a pan-European approval [378641] and is …
Pegasys, Dale L. Barnard
Pegasys, Dale L. Barnard
Animal, Dairy, and Veterinary Science Faculty Publications
No abstract provided.